From undruggable to actionable: advances in KRAS targeting in colorectal cancer
KRAS (Kristen rat sarcoma viral oncogene homolog) mutations occur in approximately 40–50% of metastatic colorectal cancer (CRC) cases and have long been associated with resistance to anti-epidermal growth factor receptor (EGFR) therapies and poor clinical outcomes. Historically considered...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Academia.edu Journals
2026-04-01
|
| Col·lecció: | Academia Oncology |
| Accés en línia: | https://www.academia.edu/165525801/From_undruggable_to_actionable_advances_in_KRAS_targeting_in_colorectal_cancer |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|